Cancer cells are notorious for evading the immune system, forming protective barriers that make them difficult to target and destroy. While immune cells such as T cells are capable of attacking cancer, tumors often create an environment that neutralizes these defenses. Now, scientists have developed a new gene therapy that reprograms tumor cells into immune cells, effectively turning the cancer against itself.

The New Approach: Cellular Reprogramming

A research team from Asgard Therapeutics and Lund University has developed a method to reprogram cancer cells into cDC1 cells, a type of immune cell that plays a key role in coordinating the body’s immune response. The process involves using transcription factors—proteins that can turn genes on or off—to change the identity of cancer cells. These reprogrammed cells then help dismantle the tumor’s protective shield, allowing the immune system to attack the cancer more effectively.

Key Discovery Description
Reprogramming Tumor Cells Tumor cells are converted into cDC1 immune cells using transcription factors
cDC1 Cells Rare immune cells that help coordinate powerful immune responses
Protective Shield Reprogrammed cells break down the tumor's defense and recruit T cells to attack

How Cellular Reprogramming Works

At the heart of this new therapy is cellular reprogramming. By using transcription factors, the scientists can switch a cancer cell’s identity to that of an immune cell. This concept isn’t entirely new—similar technology was used to develop pluripotent stem cells (iPSCs), which earned a Nobel Prize. However, reprogramming tumor cells is more complex due to their inherent abnormalities.

In the new study, the researchers identified three transcription factors capable of turning cancer cells into cDC1 cells. They used a virus to deliver these factors into the tumor cells. Once inside, the tumor cells began transforming into immune cells, triggering a powerful immune response that targeted the cancer.

Cellular Reprogramming Process Description
Transcription Factors Proteins that switch the identity of tumor cells to cDC1 immune cells
Delivery Method Genetic sequences are inserted into tumor cells using a virus
Immune Response Reprogrammed cells activate immune cells, weakening the tumor's defenses

Promising Results in Mice

In a series of tests, the researchers applied the gene therapy to melanoma tumors in mice. The results were striking: mice treated with the reprogramming therapy remained cancer-free for over 100 days, and their immune systems were able to fend off cancer relapse in lab tests. The therapy also dramatically increased the number of memory T cells, which help the body recognize and attack previously defeated tumors.

Study Results in Mice Description
Cancer-Free Mice Treated mice remained cancer-free for over 100 days
Immune Memory Boosted number of memory T cells to prevent cancer resurgence
Effect on Tumor Barrier Treatment dismantled the tumor's protective shield, allowing immune cells to attack

The transformed cDC1 cells didn’t just break down the tumors’ protective barriers—they also prevented the exhaustion of T cells, a common issue in cancer immunotherapy. Exhausted T cells lose their ability to attack cancer cells effectively, but the reprogrammed immune cells kept them functional, improving their cancer-killing capacity.

T Cell Function Description
Reduced T Cell Exhaustion Reprogrammed cells prevented immune cell exhaustion, boosting T cell effectiveness
Memory T Cells Retained memory of previous cancer attacks, guarding against cancer resurgence

The Future: Could This Work in Humans?

While the therapy showed success in mice, its potential for use in human cancers is still being explored. The team also tested the therapy on cancer cell lines and tumor spheroids—3D models of human tumors grown in petri dishes. The results were promising, with the reprogrammed cells helping to shrink the tumors. However, the efficiency of the therapy varied across different types of cancer.

In the final test, the researchers injected the gene therapy directly into tumors in mice, bypassing the need to extract and reprogram cells outside the body. Half of the treated mice remained cancer-free for 100 days, and many resisted cancer relapse for an additional 60 days.

Human Application Description
Cell Line Tests Tested on human cancer cell lines; results varied by cancer type
In Vivo Tests Direct injection into tumors in mice showed strong results, preventing cancer relapse

Moving Toward Human Trials

Although the treatment is still in the preclinical phase, the team is optimistic about moving toward human clinical trials. They are currently testing the therapy’s safety profiles, examining drug metabolism, and scaling up the production of the treatment for larger studies. The goal is to bring this reprogramming technology to clinics as a first-in-class cancer immunotherapy that could work across multiple cancer types.

Next Steps Description
Safety Testing Evaluating safety and metabolism before moving to human trials
Scaling Up Scaling up manufacturing processes for larger studies
Clinical Trials Preparing for human clinical trials to test efficacy in human cancers

A New Class of Cancer Immunotherapy

This innovative approach represents a new class of immunotherapy, where tumor cells are reprogrammed into immune cells to fight the very cancer they once belonged to. The technology offers precision targeting of cancer cells, potentially overcoming the limitations of current therapies like CAR T therapy. If successful in humans, it could pave the way for personalized cancer treatments that adapt to the unique makeup of each patient’s tumor.

“Turning tumor cells against themselves offers the advantages of precision cell therapy while overcoming the challenges of genetic engineering,” the authors concluded.

More Information:

💛 Support the Editor

If you liked this post and would like to support the editor through a financial donation then you can do so below!

💛 Donate